MedTrace Logo

Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study

NCT06599463 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 351

Last updated 2025-03-20

No results posted yet for this study

Summary

LARENA is a multicentric retrospective study (secondary use of data) of consecutive patients prospectively registered in the lenvatinib plus pembrolizumab French early access program (Temporary Authorisation for Use). The source of data will be the patient's medical file. We will manually review all files of the participating centers.

Conditions

  • Metastatic Endometrial Cancer

Sponsors & Collaborators

  • Institut Curie

    collaborator OTHER

  • ARCAGY/ GINECO GROUP

    lead OTHER

Principal Investigators

  • Diana BELLO ROUFAI · Institut Curie

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-19
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06599463 on ClinicalTrials.gov